These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12736113)
1. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A; Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113 [TBL] [Abstract][Full Text] [Related]
2. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895 [TBL] [Abstract][Full Text] [Related]
3. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168 [TBL] [Abstract][Full Text] [Related]
4. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
5. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336 [TBL] [Abstract][Full Text] [Related]
6. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA). Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925 [TBL] [Abstract][Full Text] [Related]
7. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]. Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312 [TBL] [Abstract][Full Text] [Related]
8. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297 [TBL] [Abstract][Full Text] [Related]
9. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Rosell R; Gatzemeier U; Betticher DC; Keppler U; Macha HN; Pirker R; Berthet P; Breau JL; Lianes P; Nicholson M; Ardizzoni A; Chemaissani A; Bogaerts J; Gallant G Ann Oncol; 2002 Oct; 13(10):1539-49. PubMed ID: 12377641 [TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443 [TBL] [Abstract][Full Text] [Related]
11. Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Ray-Coquard I; Paraiso D; Guastalla JP; Leduc B; Guichard F; Martin C; Chauvenet L; Haddad-Guichard Z; Lepillé D; Orfeuvre H; Gautier H; Castera D; Pujade-Lauraine E Br J Cancer; 2007 Nov; 97(9):1200-5. PubMed ID: 17923867 [TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936 [TBL] [Abstract][Full Text] [Related]
13. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Hirsch FR; Osterlind K; Jeppesen N; Dombernowsky P; Ingeberg S; Sorensen PG; Kristensen C; Hansen HH Ann Oncol; 2001 May; 12(5):647-53. PubMed ID: 11432623 [TBL] [Abstract][Full Text] [Related]
14. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Dittrich C; Sevelda P; Baur M; Marth C; Hudec M; Vavra N; Grunt T; Fazeny B; Salzer H Cancer; 1993 May; 71(10):3082-90. PubMed ID: 8490836 [TBL] [Abstract][Full Text] [Related]
17. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer]. Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544 [TBL] [Abstract][Full Text] [Related]
18. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207 [TBL] [Abstract][Full Text] [Related]
19. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. Levin L; Simon R; Hryniuk W J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257 [TBL] [Abstract][Full Text] [Related]
20. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]